LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39927 · Hematology
New LCD for myeloproliferative neoplasm testing impacts billing.
Code intelligence
D47.2 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D47.2.
Elevated code riskView ICD-10 detail
Signal breakdown
3 shown · 3 total in platform
Risk: Elevated
0
Critical
0%
1
High
33%
2
Routine
67%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
Proposed LCD DL39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-DL39927 · Oncology
Impact of LCD on billing for myeloproliferative neoplasms testing.
LCD L39189: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG) — Wellpoint Federal
Policy LCD-L39189 · Clinical Laboratory
MS testing coverage for monoclonal gammopathy now active under Wellpoint.
Audit documentation
Building an audit file that includes D47.2?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription